Compare Pharmaceutical Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 AbbVieBristol-Myers SquibbGlaxoSmithKlineMcKessonMerck & Co., Inc.
SymbolNYSE:ABBVNYSE:BMYNYSE:GSKNYSE:MCKNYSE:MRK
Price Information
Current Price$107.54$62.61$36.65$190.87$76.31
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score2.82.31.12.22.4
Analysis Score1.42.40.02.53.4
Community Score2.92.62.03.12.5
Dividend Score5.02.51.71.72.5
Ownership Score1.71.70.01.71.7
Earnings & Valuation Score3.12.51.91.91.9
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$115.75$74.64N/A$196.00$95.92
% Upside from Price Target7.63% upside19.22% upsideN/A2.69% upside25.69% upside
Trade Information
Market Cap$189.79 billion$139.87 billion$98.68 billion$30.38 billion$193.09 billion
Beta0.840.670.670.940.43
Average Volume7,499,31112,622,2965,931,7721,034,51911,916,204
Sales & Book Value
Annual Revenue$33.27 billion$26.15 billion$43.10 billion$231.05 billion$46.84 billion
Price / Sales5.715.352.290.134.12
Cashflow$10.05 per share$4.13 per share$4.22 per share$22.22 per share$6.20 per share
Price / Cash10.7015.168.698.5912.31
Book Value($5.53) per share$23.20 per share$9.40 per share$30.01 per share$10.21 per share
Price / Book-19.452.703.906.367.47
Profitability
Net Income$7.88 billion$3.44 billion$5.93 billion$900 million$9.84 billion
EPS$8.94$4.69$3.17$14.95$5.19
Trailing P/E Ratio22.74N/A11.2814.5316.88
Forward P/E Ratio8.848.5511.9010.9412.57
P/E Growth1.541.002.931.701.89
Net Margins18.16%-0.11%18.50%0.95%24.33%
Return on Equity (ROE)439.24%27.48%29.60%45.52%53.83%
Return on Assets (ROA)13.22%10.77%7.11%4.42%16.83%
Dividend
Annual Payout$5.20$1.96$2.52$1.68$2.60
Dividend Yield4.84%3.13%6.88%0.88%3.41%
Three-Year Dividend Growth84.37%46.79%-1.26%33.87%31.22%
Payout Ratio58.17%41.79%79.50%11.24%50.10%
Years of Consecutive Dividend Growth49 Years1 Years1 Years4 Years1 Years
Debt
Debt-to-Equity Ratio5.38%0.82%1.13%0.96%0.90%
Current Ratio0.95%1.67%0.90%0.99%1.30%
Quick Ratio0.81%1.58%0.61%0.56%1.00%
Ownership Information
Institutional Ownership Percentage67.49%72.41%11.83%85.60%72.86%
Insider Ownership Percentage0.09%0.14%10.00%0.28%0.28%
Miscellaneous
Employees47,00030,25099,43780,00073,000
Shares Outstanding1.76 billion2.23 billion2.69 billion159.17 million2.53 billion
Next Earnings Date4/30/2021 (Confirmed)4/29/2021 (Confirmed)5/5/2021 (Estimated)5/6/2021 (Confirmed)4/29/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable

Latest Pharmaceutical News

SourceHeadline
Merck Stock – Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer StudyMerck Stock – Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
fintechzoom.com - April 9 at 11:43 PM
Bonness Enterprises Inc Buys Merck IncBonness Enterprises Inc Buys Merck Inc
finance.yahoo.com - April 9 at 11:43 PM
Merck Stock – Merck (MRK) Stock Sinks As Market Gains: What You Should KnowMerck Stock – Merck (MRK) Stock Sinks As Market Gains: What You Should Know
fintechzoom.com - April 9 at 1:42 PM
Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer StudyMerck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
finance.yahoo.com - April 9 at 1:42 PM
3 Stocks Near 52-Week Lows Ready to Buy3 Stocks Near 52-Week Lows Ready to Buy
marketbeat.com - April 9 at 1:24 PM
Organon Announces Pricing of Senior Notes OfferingOrganon Announces Pricing of Senior Notes Offering
finance.yahoo.com - April 9 at 12:12 AM
Mercks Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney CancerMerck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer
finance.yahoo.com - April 8 at 7:07 PM
May 28th Options Now Available For Merck (MRK)May 28th Options Now Available For Merck (MRK)
nasdaq.com - April 8 at 2:07 PM
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following SurgeryMerck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
finance.yahoo.com - April 8 at 9:07 AM
Organon Announces Proposed Senior Notes OfferingOrganon Announces Proposed Senior Notes Offering
finance.yahoo.com - April 6 at 7:24 PM
Merck & Co., Inc. (NYSE:MRK) Expected to Post Quarterly Sales of $12.85 BillionMerck & Co., Inc. (NYSE:MRK) Expected to Post Quarterly Sales of $12.85 Billion
americanbankingnews.com - April 4 at 1:42 AM
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder CancerMerck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer
finance.yahoo.com - March 31 at 11:56 AM
Mercks (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)
finance.yahoo.com - March 31 at 11:56 AM
Mercks (MRK) Breast Cancer sBLA for Keytruda Gets CRLMerck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL
nasdaq.com - March 30 at 2:23 PM
The Rockefeller Foundation is teaming up with COVID-19 testing companies to reopen schools safelyThe Rockefeller Foundation is teaming up with COVID-19 testing companies to reopen schools safely
finance.yahoo.com - March 30 at 2:22 PM
What Does Merck & Cos Debt Look Like?What Does Merck & Co's Debt Look Like?
benzinga.com - March 30 at 9:21 AM
Could Mercks New Antiviral Be the Next Big COVID Treatment?Could Merck's New Antiviral Be the Next Big COVID Treatment?
finance.yahoo.com - March 30 at 9:21 AM
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial CancerMerck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - March 30 at 9:21 AM
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of OrganonMerck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
finance.yahoo.com - March 30 at 9:21 AM
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - March 29 at 6:20 PM
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
finance.yahoo.com - March 29 at 8:14 AM
Merck Stock – Why Merck (MRK) is a Top Dividend Stock for Your PortfolioMerck Stock – Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
fintechzoom.com - March 27 at 12:55 AM
Rutgers University to require COVID-19 vaccinations this fallRutgers University to require COVID-19 vaccinations this fall
finance.yahoo.com - March 26 at 2:54 PM
Vaccination distribution is ‘a race against time’ as variants spread: Doctor Vaccination distribution is ‘a race against time’ as variants spread: Doctor 
finance.yahoo.com - March 26 at 2:54 PM
Is Merck Stock A Buy As It Teams Up To Produce J&Js Covid Vaccine?Is Merck Stock A Buy As It Teams Up To Produce J&J's Covid Vaccine?
finance.yahoo.com - March 26 at 9:53 AM
How Gileads and Mercks Surprise Partnership Will Shake Up the HIV MarketHow Gilead's and Merck's Surprise Partnership Will Shake Up the HIV Market
finance.yahoo.com - March 25 at 8:40 AM

Latest Pharmaceutical Analyst Ratings

DateCompanyBrokerageAction
4/7/2021AbbVieRoyal Bank of CanadaInitiated Coverage
3/30/2021AbbVieSVB LeerinkBoost Price Target
2/4/2021AbbVieMizuhoBoost Price Target
1/28/2021AbbVieMorgan StanleyLower Price Target
11/18/2020AbbVieBMO Capital MarketsInitiated Coverage
11/10/2020AbbVieSanford C. BernsteinInitiated Coverage
10/23/2020AbbVieTruistInitiated Coverage
10/20/2020AbbVieThe Goldman Sachs GroupDowngrade
10/16/2020AbbVieJPMorgan Chase & Co.Boost Price Target
9/29/2020AbbVieBerenberg BankInitiated Coverage
9/2/2020AbbVieCitigroupBoost Price Target
6/23/2020AbbVieAtlantic SecuritiesUpgrade
11/30/2020Bristol-Myers SquibbCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
11/30/2020Bristol-Myers SquibbSmith Barney CitigroupBoost Price Target
11/16/2020Bristol-Myers SquibbSociete GeneraleUpgrade
11/6/2020Bristol-Myers SquibbGabelliDowngrade
10/19/2020Bristol-Myers SquibbGuggenheimUpgrade
9/25/2020Bristol-Myers SquibbRaymond JamesReiterated Rating
7/28/2020Bristol-Myers SquibbSeaport Global SecuritiesInitiated Coverage
7/26/2020Bristol-Myers SquibbCfraReiterated Rating
6/2/2020Bristol-Myers SquibbCantor FitzgeraldBoost Price Target
6/1/2020Bristol-Myers SquibbWilliam BlairReiterated Rating
5/15/2020Bristol-Myers SquibbBank of AmericaReiterated Rating
2/27/2020Bristol-Myers SquibbBarclaysInitiated Coverage
2/8/2021GlaxoSmithKlineUBS GroupReiterated Rating
2/3/2021GlaxoSmithKlineDeutsche Bank AktiengesellschaftDowngrade
1/20/2021GlaxoSmithKlineCredit Suisse GroupDowngrade
12/16/2020GlaxoSmithKlineDZ BankReiterated Rating
11/2/2020GlaxoSmithKlineLiberum CapitalUpgrade
9/23/2020GlaxoSmithKlineOddo BhfUpgrade
3/30/2021McKessonArgusUpgrade
3/2/2021McKessonCowenBoost Price Target
5/22/2020McKessonWolfe ResearchUpgrade
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.